Hiromi Matsumoto

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Venues

PloS one

Cancers

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayash, Yuuki Higashino, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Kohei Somekawa, Ayami Kaneko, Ryo Nagasawa, Sousuke Kubo, Katsushi Tanaka, Kota Murohashi, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse. PloS one 19 (8) (2024)
Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayash, Yuuki Higashino, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Kohei Somekawa, Ayami Kaneko, Ryo Nagasawa, Sousuke Kubo, Katsushi Tanaka, Kota Murohashi, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse. PloS one 19 (8) (2024)
Hiromi Matsumoto, Kohei Somekawa, Nobuyuki Horita, Suguru Ueda, Megumi Kaneko, Ayami Kaneko, Nobuhiko Fukuda, Ami Izawa, Chisato Kamimaki, Katsushi Tanaka, Kota Murohashi, Hiroaki Fuji, Yoichi Tagami, Ayako Aoki, Keisuke Watanabe, Yu Hara, Nobuaki Kobayash, Takeshi Kaneko
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis. Therapeutic advances in medical oncology 15 (2023)
Nobuaki Kobayash, Kenji Miura, Ayami Kaneko, Hiromi Matsumoto, Kohei Somekawa, Tomofumi Hirose, Yukihito Kajita, Anna Tanaka, Shuhei Teranishi, Yu Sairenji, Hidetoshi Kawashima, Kentaro Yumoto, Toshinori Tsukahara, Nobuhiko Fukuda, Ryuichi Nishihira, Makoto Kudo, Naoki Miyazawa, Takeshi Kaneko
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes. Cancers 15 (21) (2023)

Hiromi Matsumoto.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiromi Matsumoto